Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Howard Lee Weiner, M.D.

Co-Author

This page shows the publications co-authored by Howard Weiner and David Hafler.
Connection Strength

5.529
  1. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev. 1995 Apr; 144:75-107.
    View in: PubMed
    Score: 0.163
  2. Therapy for multiple sclerosis. Neurol Clin. 1995 Feb; 13(1):173-96.
    View in: PubMed
    Score: 0.161
  3. Antigen specific therapies for the treatment of autoimmune diseases. Agents Actions Suppl. 1995; 47:59-77.
    View in: PubMed
    Score: 0.160
  4. Antigen-specific immunosuppression: oral tolerance for the treatment of autoimmune disease. Chem Immunol. 1995; 60:126-49.
    View in: PubMed
    Score: 0.160
  5. Antigen-specific therapies for the treatment of autoimmune diseases. Springer Semin Immunopathol. 1995; 17(1):61-76.
    View in: PubMed
    Score: 0.160
  6. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994; 12:809-37.
    View in: PubMed
    Score: 0.149
  7. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26; 259(5099):1321-4.
    View in: PubMed
    Score: 0.141
  8. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol. 1992 Mar; 62(3):307-13.
    View in: PubMed
    Score: 0.131
  9. The potential of restricted T cell recognition of myelin basic protein epitopes in the therapy of multiple sclerosis. Ann N Y Acad Sci. 1991 Dec 30; 636:251-65.
    View in: PubMed
    Score: 0.130
  10. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol. 1991 May; 32(2):149-58.
    View in: PubMed
    Score: 0.124
  11. Interleukin-1 corrects the defective autologous mixed lymphocyte response in multiple sclerosis. Clin Immunol Immunopathol. 1991 Jan; 58(1):115-25.
    View in: PubMed
    Score: 0.121
  12. MS: a CNS and systemic autoimmune disease. Immunol Today. 1989 Mar; 10(3):104-7.
    View in: PubMed
    Score: 0.107
  13. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A. 2009 Mar 31; 106(13):5264-9.
    View in: PubMed
    Score: 0.107
  14. Immunoregulation in multiple sclerosis. Res Immunol. 1989 Feb; 140(2):233-9; discussion 245-8.
    View in: PubMed
    Score: 0.106
  15. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol. 1988 Jul 01; 141(1):131-8.
    View in: PubMed
    Score: 0.102
  16. Immunosuppression with monoclonal antibodies in multiple sclerosis. Neurology. 1988 Jul; 38(7 Suppl 2):42-7.
    View in: PubMed
    Score: 0.102
  17. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain. 2008 Jul; 131(Pt 7):1701-11.
    View in: PubMed
    Score: 0.102
  18. Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J Neuroimmunol. 2008 Mar; 195(1-2):140-5.
    View in: PubMed
    Score: 0.100
  19. Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1988 Apr 01; 167(4):1313-22.
    View in: PubMed
    Score: 0.100
  20. Immunotherapy of multiple sclerosis. Ann Neurol. 1988 Mar; 23(3):211-22.
    View in: PubMed
    Score: 0.100
  21. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human antimouse responses. Ann N Y Acad Sci. 1988; 540:557-9.
    View in: PubMed
    Score: 0.098
  22. T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol Rev. 1987 Dec; 100:307-32.
    View in: PubMed
    Score: 0.098
  23. Secondary immune amplification following live poliovirus immunization in humans. Clin Immunol Immunopathol. 1987 Sep; 44(3):321-8.
    View in: PubMed
    Score: 0.096
  24. Myelin basic protein and proteolipid protein reactivity of brain- and cerebrospinal fluid-derived T cell clones in multiple sclerosis and postinfectious encephalomyelitis. J Immunol. 1987 Jul 01; 139(1):68-72.
    View in: PubMed
    Score: 0.095
  25. In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann Neurol. 1987 Jul; 22(1):89-93.
    View in: PubMed
    Score: 0.095
  26. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol. 2006 Sep 15; 177(6):4196-202.
    View in: PubMed
    Score: 0.090
  27. Antigen reactive memory T cells are defined by Ta1. J Immunol. 1986 Jul 15; 137(2):414-8.
    View in: PubMed
    Score: 0.089
  28. Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology. 1986 Jun; 36(6):777-84.
    View in: PubMed
    Score: 0.088
  29. Monoclonal gammopathy and neuropathy: myelin-associated glycoprotein reactivity and clinical characteristics. Neurology. 1986 Jan; 36(1):75-8.
    View in: PubMed
    Score: 0.086
  30. Investigation of in vivo activated T cells in multiple sclerosis and inflammatory central nervous system diseases. Clin Immunol Immunopathol. 1985 Nov; 37(2):163-71.
    View in: PubMed
    Score: 0.085
  31. Phenotypic and functional analysis of T cells cloned directly from the blood and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol. 1985 Oct; 18(4):451-8.
    View in: PubMed
    Score: 0.084
  32. Decreased autologous mixed lymphocyte reaction in multiple sclerosis. J Neuroimmunol. 1985 Oct; 9(6):339-47.
    View in: PubMed
    Score: 0.084
  33. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 1985 May 30; 312(22):1405-11.
    View in: PubMed
    Score: 0.082
  34. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004 Apr 05; 199(7):971-9.
    View in: PubMed
    Score: 0.076
  35. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler. 1999 Dec; 5(6):403-9.
    View in: PubMed
    Score: 0.056
  36. Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis. J Neuroimmunol. 1998 Nov 02; 91(1-2):1-9.
    View in: PubMed
    Score: 0.052
  37. Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol. 1998 Jul; 88(1):28-34.
    View in: PubMed
    Score: 0.051
  38. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci. 1997 Dec 19; 835:120-31.
    View in: PubMed
    Score: 0.049
  39. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol. 1997 Sep; 42(3):313-8.
    View in: PubMed
    Score: 0.048
  40. Oral administration of myelin induces antigen-specific TGF-beta 1-secreting T cells in multiple sclerosis patients. Ann N Y Acad Sci. 1997 Apr 05; 815:412-22.
    View in: PubMed
    Score: 0.047
  41. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997 Jan 21; 94(2):599-603.
    View in: PubMed
    Score: 0.046
  42. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 1996 Jul 01; 98(1):70-7.
    View in: PubMed
    Score: 0.044
  43. Power estimation for non-standardized multisite studies. Neuroimage. 2016 07 01; 134:281-294.
    View in: PubMed
    Score: 0.044
  44. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. Ann N Y Acad Sci. 1996 Feb 13; 778:243-50.
    View in: PubMed
    Score: 0.043
  45. Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis. Ann N Y Acad Sci. 1996 Feb 13; 778:251-7.
    View in: PubMed
    Score: 0.043
  46. Pilot study of oral tolerance to keyhole limpet hemocyanin in humans: down-regulation of KLH-reactive precursor-cell frequency. Ann N Y Acad Sci. 1996 Feb 13; 778:398-404.
    View in: PubMed
    Score: 0.043
  47. Role of Th1 and Th2 cells in neurologic disorders. Chem Immunol. 1996; 63:171-86.
    View in: PubMed
    Score: 0.043
  48. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest. 1995 Jun; 95(6):2711-9.
    View in: PubMed
    Score: 0.041
  49. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994 Aug 26; 265(5176):1237-40.
    View in: PubMed
    Score: 0.039
  50. T cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: studies with TCR V beta 8.2 transgenic mice. J Exp Med. 1994 May 01; 179(5):1659-64.
    View in: PubMed
    Score: 0.038
  51. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994 Mar 01; 179(3):973-84.
    View in: PubMed
    Score: 0.038
  52. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.037
  53. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993 Sep 24; 261(5129):1727-30.
    View in: PubMed
    Score: 0.037
  54. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 May; 43(5):910-8.
    View in: PubMed
    Score: 0.036
  55. Biological activity of recombinant human myelin basic protein. J Neuroimmunol. 1993 May; 44(2):157-62.
    View in: PubMed
    Score: 0.036
  56. The development of antigen specific therapies for autoimmune diseases; investigations in multiple sclerosis as a paradigm for rheumatoid arthritis. Clin Exp Rheumatol. 1993 Mar-Apr; 11 Suppl 8:S39-40.
    View in: PubMed
    Score: 0.035
  57. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
    View in: PubMed
    Score: 0.034
  58. Autoreactive T cells in multiple sclerosis. Int Rev Immunol. 1992; 9(3):183-201.
    View in: PubMed
    Score: 0.032
  59. Immunotherapy in autoimmune diseases. Curr Opin Immunol. 1991 Dec; 3(6):936-40.
    View in: PubMed
    Score: 0.032
  60. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases. FASEB J. 1991 Aug; 5(11):2560-6.
    View in: PubMed
    Score: 0.032
  61. T-cell recognition of myelin basic protein. Immunol Today. 1991 Aug; 12(8):277-82.
    View in: PubMed
    Score: 0.032
  62. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig. Ann Neurol. 1991 Jun; 29(6):615-22.
    View in: PubMed
    Score: 0.031
  63. Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Ann Neurol. 1991 Jan; 29(1):33-40.
    View in: PubMed
    Score: 0.030
  64. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 Apr; 233(1-2):168-74.
    View in: PubMed
    Score: 0.030
  65. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010 Sep; 67(9):1055-61.
    View in: PubMed
    Score: 0.030
  66. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.030
  67. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990 Jul 12; 346(6280):183-7.
    View in: PubMed
    Score: 0.029
  68. Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science. 1990 May 25; 248(4958):1016-9.
    View in: PubMed
    Score: 0.029
  69. Inflammatory cerebrospinal fluid T cells have activation requirements characteristic of CD4+CD45RA- T cells. Eur J Immunol. 1989 Oct; 19(10):1791-5.
    View in: PubMed
    Score: 0.028
  70. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009 Jul; 41(7):776-82.
    View in: PubMed
    Score: 0.027
  71. Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 1989 May; 25(5):494-9.
    View in: PubMed
    Score: 0.027
  72. Sequestration of virus-specific T cells in the cerebrospinal fluid of a patient with varicella zoster viral meningoencephalitis. J Neuroimmunol. 1989 Mar; 22(1):63-8.
    View in: PubMed
    Score: 0.027
  73. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008 Sep 16; 71(12):917-24.
    View in: PubMed
    Score: 0.026
  74. Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4+ 2H4+) T cells in multiple sclerosis. Ann Neurol. 1988 Aug; 24(2):185-91.
    View in: PubMed
    Score: 0.026
  75. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology. 1988 Jul; 38(7 Suppl 2):9-14.
    View in: PubMed
    Score: 0.025
  76. The 2H4 (CD45R) antigen is selectively decreased in multiple sclerosis lesions. J Immunol. 1988 Apr 01; 140(7):2210-4.
    View in: PubMed
    Score: 0.025
  77. Cumulative experience with high-dose intravenous cyclophosphamide and ACTH therapy in chronic progressive multiple sclerosis. Ann N Y Acad Sci. 1988; 540:535-6.
    View in: PubMed
    Score: 0.025
  78. Immunohistochemical analysis of suppressor-inducer and helper-inducer T cells in multiple sclerosis brain tissue. Ann N Y Acad Sci. 1988; 540:306-8.
    View in: PubMed
    Score: 0.025
  79. Loss of functional suppression is linked to decreases in circulating suppressor-inducer (CD4+ 2H4+) T cells in multiple sclerosis. Ann N Y Acad Sci. 1988; 540:330-2.
    View in: PubMed
    Score: 0.025
  80. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. Riv Neurol. 1987 Mar-Apr; 57(2):88-91.
    View in: PubMed
    Score: 0.023
  81. Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. J Neuroimmunol. 1986 Nov; 13(1):99-108.
    View in: PubMed
    Score: 0.023
  82. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol. 2004 Aug; 230(2):89-98.
    View in: PubMed
    Score: 0.019
  83. Autoimmunity following viral infection: demonstration of monoclonal antibodies against normal tissue following infection of mice with reovirus and demonstration of shared antigenicity between virus and lymphocytes. Eur J Immunol. 1984 Jun; 14(6):561-5.
    View in: PubMed
    Score: 0.019
  84. Altered blood T-cell subsets in patients with multiple sclerosis. J Neuroimmunol. 1984 Apr; 6(2):115-21.
    View in: PubMed
    Score: 0.019
  85. The use of cyclophosphamide in the treatment of multiple sclerosis. Ann N Y Acad Sci. 1984; 436:373-81.
    View in: PubMed
    Score: 0.019
  86. T cell subsets in patients with multiple sclerosis. An overview. Ann N Y Acad Sci. 1984; 436:281-93.
    View in: PubMed
    Score: 0.019
  87. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997 May; 123(5):583-92.
    View in: PubMed
    Score: 0.012
  88. Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. N Engl J Med. 1987 Jan 08; 316(2):67-72.
    View in: PubMed
    Score: 0.006
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.